WHO ICTRP trial
Palbociclib plus letrozole for menopausal women with localized breast cancer
EUCTR2019-004899-19-FR · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2019-004899-19-FR |
|---|---|
| Public title | Palbociclib plus letrozole for menopausal women with localized breast cancer |
| Scientific title | Adjuvant PalbOciclib + LetrOzole combination for hormone receptor positive / HER2-negative, Intermediate Risk breast cancer - APOLON |
| Primary sponsor | UNICANCER |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | France |
| Conditions | Hormone receptor (HR) positive / HER2-negative localized breast cancer in menopausal patient considered as having an intermediate risk of relapse.;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Trade Name: IBRANCE 125mg Pharmaceutical Form: Capsule INN or Proposed INN: PALBOCICLIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 125- Trade Name: IBRANCE 100mg Pharmaceutical Form: Capsule INN or… |
| Registration date | Apr 16, 2020 |
| Target size | 1500 |
| Secondary IDs | UC-BCG-1911 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: